A study comparing the efficacy, quality of life and toxicity of cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer in the Indian scenario Source: Annual Congress 2011 - Palliation and morbidity in lung cancer patients Year: 2011
Radiation therapy for augmenting the efficacy of immunotherapy in advanced non-small cell lung cancer: a case-controlled study Source: ERJ Open Res, 6 (1) 00189-2019; 10.1183/23120541.00189-2019 Year: 2020
Factors predicting complete surgical resection after induction chemotherapy in patients with initially unresectable non-small cell lung cancer (NSCLC) treated in a randomised trial Source: Eur Respir J 2003; 22: Suppl. 45, 162s Year: 2003
Pre-operative chemotherapy in patients with resectable non-small cell lung cancer (NSCLC): the MRC LU22/NVALT/EORTC 08012 multi-centre randomised trial Source: Eur Respir J 2007; 30: Suppl. 51, 240s Year: 2007
Comparison of quality of life in patients with non-small cell lung cancer treated by chemotherapy or radiotherapy Source: Eur Respir J 2004; 24: Suppl. 48, 75s Year: 2004
The big lung trial (BLT): determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the radical radiotherapy setting Source: Eur Respir J 2003; 22: Suppl. 45, 163s Year: 2003
A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 162s Year: 2003
Impact of neoadjuvant therapy on tumor resectability and survival of patients with locally advanced non-small cell lung cancer Source: Annual Congress 2011 - General thoracic surgery II Year: 2011
Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer Source: ERJ Open Res, 4 (2) 00120-2017; 10.1183/23120541.00120-2017 Year: 2018
Salvage surgery in patients with locally advanced non-small cell lung cancer – outcomes and longtime results Source: Virtual Congress 2021 – Therapy of lung cancer Year: 2021
Renal impairment during pemetrexed maintenance in patients with advanced nonsmall cell lung cancer: a cohort study Source: Eur Respir J, 52 (4) 1800884; 10.1183/13993003.00884-2018 Year: 2018
Should patients with metastatic NSCLC and poor performance status be treated by chemotherapy? Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies Year: 2007
Role of chemotherapy in stage III non-small cell lung cancer (NSCLC): adjuvant or induction? Source: Annual Congress 2006 - Integrative approaches for stage III non-small cell lung cancer Year: 2006
Lung function evaluation in gemcitabine and concurrent radiotherapy treatment in nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 376s Year: 2001
The 7-year results of the surgical treatment of non-small cell lung cancer (NSCLC) patients and the influence of neoadjuvant treatment Source: Annual Congress 2007 - Therapy of thoracic malignancies Year: 2007
Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives Source: Eur Respir Rev 2011; 20: 45-52 Year: 2011
First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodology Source: Eur Respir Rev 2014; 23: 92-105 Year: 2014
A cost minimisation comparison of five chemotherapy regimes for advanced nonsmall cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 431s Year: 2003
Treatment of advanced non-small cell lung cancer Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment Year: 2005
Phase I/II study of biweekly docetaxel/cisplatin with concurrent thoracic radiotherapy for locally advanced non-small cell lung cancer Source: Annual Congress 2005 - Chemotherapy and palliative care Year: 2005